Cargando…

Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation

BACKGROUND: Protein markers of cellular proliferation, hypoxia, apoptosis, cell cycle checkpoints, growth factor signalling and inflammation in localised prostate tumours have previously shown prognostic ability. A translational substudy within the CHHiP trial of radiotherapy fractionation evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkins, Anna, Gusterson, Barry, Tovey, Holly, Griffin, Clare, Stuttle, Christine, Daley, Frances, Corbishley, Catherine M., Dearnaley, David, Hall, Emma, Somaiah, Navita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900483/ https://www.ncbi.nlm.nih.gov/pubmed/36708693 http://dx.doi.org/10.1016/j.ebiom.2023.104436

Ejemplares similares

Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer
por: Wilkins, Anna, et al.
Publicado: (2018)

Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer
por: Wilkins, Anna C., et al.
Publicado: (2018)

Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial
por: Murray, Julia, et al.
Publicado: (2019)

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity
por: Naismith, O.F., et al.
Publicado: (2019)

Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial
por: Brand, Douglas H., et al.
Publicado: (2021)

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Wilkins, Anna, et al.
Publicado: (2015)

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
por: Staffurth, John N., et al.
Publicado: (2021)

Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity
por: Lemanska, Agnieszka, et al.
Publicado: (2017)

Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice
por: Lemanska, Agnieszka, et al.
Publicado: (2020)

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
por: Tree, Alison, et al.
Publicado: (2022)

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Dearnaley, David, et al.
Publicado: (2016)

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer
por: Wilkins, Anna, et al.
Publicado: (2015)

TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells
por: Anbalagan, Selvakumar, et al.
Publicado: (2021)

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
por: Wilkins, Anna, et al.
Publicado: (2018)

Radiotherapy fraction size sensitivity is modulated by DNA repair systems
por: Somaiah, N, et al.
Publicado: (2010)

Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology
por: Sobhani, Faranak, et al.
Publicado: (2021)

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial
por: Brunt, A. Murray, et al.
Publicado: (2016)

An ionising radiation-induced specific transcriptional signature of inflammation-associated genes in whole blood from radiotherapy patients: a pilot study
por: Cruz-Garcia, Lourdes, et al.
Publicado: (2021)

Establishing a controlled hookworm human infection (CHHI) model for Africa: A report from the stakeholders meeting held in Lambaréné, Gabon, November 10–11, 2019
por: Alabi, Ayodele, et al.
Publicado: (2021)

Identification of Novel Biomarker Candidates for the Immunohistochemical Diagnosis of Cholangiocellular Carcinoma
por: Padden, Juliet, et al.
Publicado: (2014)

Basal-like Breast Cancers: From Pathology to Biology and Back Again
por: Gusterson, Barry, et al.
Publicado: (2018)

PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance
por: Feng, Hugang, et al.
Publicado: (2022)

RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma
por: Hiratsuka, Takuya, et al.
Publicado: (2022)

A prophylactic vaccine for breast cancer?
por: Watson, Christine J, et al.
Publicado: (2010)

Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers
por: Machiels, Melanie, et al.
Publicado: (2023)

Do we now have a relevant animal model for breast cancer?
por: Gusterson, Barry, et al.
Publicado: (1999)

Construction of tissue microarrays from prostate needle biopsy specimens
por: Jhavar, S, et al.
Publicado: (2005)

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)

Spatially fractionated radiotherapy (GRID) using helical tomotherapy
por: Zhang, Xin, et al.
Publicado: (2016)

Immunohistochemical Evaluation of Candidate Biomarkers for Fluorescence-Guided Surgery of Myxofibrosarcoma Using an Objective Scoring Method
por: Rijs, Zeger, et al.
Publicado: (2023)

Premalignancy in the human breast: how is it defined, is morphology good enough?
por: Gusterson, BA
Publicado: (2003)

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer
por: Gusterson, Barry A, et al.
Publicado: (2005)

Candidate Glycoprotein Biomarkers for Canine Visceral Hemangiosarcoma and Validation Using Semi-Quantitative Lectin/Immunohistochemical Assays
por: Oungsakul, Patharee, et al.
Publicado: (2021)

Potential Risk Factors of Brucellosis in Dairy Farmers of Peri-urban Areas of South West Delhi
por: Yadav, Navita, et al.
Publicado: (2020)

Learning progression toward a measurement concept of fractions
por: Wilkins, Jesse L. M., et al.
Publicado: (2018)

Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in Libya
por: Ermiah, Eramah, et al.
Publicado: (2012)

Effect of UVC Radiation on Hydrated and Desiccated Cultures of Slightly Halophilic and Non-Halophilic Methanogenic Archaea: Implications for Life on Mars
por: Sinha, Navita, et al.
Publicado: (2018)

Fetal ultrasound parameters: Reference values for a local perspective
por: Aggarwal, Navita, et al.
Publicado: (2020)

Hyper-Fractionated Radiotherapy for Soft Tissue Sarcoma: Results of the Second Study of Hyper-Fractionated Radiotherapy
por: Jacob, R., et al.
Publicado: (1999)

Fractional carbon dioxide laser alone and as an assisted drug delivery for treatment of alopecia areata: a clinical, dermoscopic and immunohistochemical study
por: Meguid, Azza Mahfouz Abdel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d007p1p08o2t8t5mfjcd82nv33